Danaher Corporation Rarely Cheap, But A Proven Winner

Danaher is no bargain, but the turnaround in the diagnostics business has been impressive.

Feb 11, 2014 at 9:37AM

If you're looking for a well-run conglomerate trading at a significant discount to fair value, you're probably going to pass over Danaher (NYSE:DHR). That's typically the case, though, as this company's demonstrated strength in generating margins, cash flow, and returns on capital makes it a perennial favorite with institutional investors.

Even if the expected returns from the stock don't meet your hurdle rate today, Danaher looks like a good name for a watch list. Management has over $8 billion in dry powder for M&A activity and a clear desire to do a large deal (or two). Combine that with a turned-around diagnostics business and underappreciated growth opportunities in product ID and water treatment, and this is a company with solid long-term prospects.

Growth seems to be picking up a bit
When Danaher reported earnings in January, the company delivered 3.5% "core" revenue growth, a slight acceleration from the 3% growth seen in the third quarter. All of the major reporting segments were up, with test & measurement providing its best performance in quite some time. Life sciences & diagnostics also continues to perform well, with strong sale performance in clinical automation and the Chinese diagnostics business.

Danaher saw a slight pick up in gross margin and managed to leverage the 6% reported revenue increase into a slightly greater than 6% operating income improvement, excluding a $31 million pre-tax impairment charge. Test and measurement did well on that revenue growth (with segment income up 11%), and the LS&D business was a major contributor to earnings growth as operating income rose more than 23% on a 2.5% improvement in operating margin.

Diagnostics is healthy again
Danaher has done an excellent job of turning around Beckman Coulter, and this division's operating margins are now basically in line with the norms of the industry. Now the question is more about where the company wants to take this business in the future.

Amidst Roche, Abbott (NYSE:ABT), and Siemens, Danaher is one of the largest players in immunoassay, a $4 billion-plus/year segment of diagnostics. Danaher is also quite strong in clinical chemistry, where it competes with a similar roster of rivals. One of the key factors here is the ongoing automation of the diagnostics space. Roche is quite strong in automation, but Abbott and Siemens have been lagging – giving Danaher a real opportunity to gain share (particularly in clinical chemistry). If Abbott does not improve its automation efforts, there is a real chance for Danaher to grab share in the large lab market, and Siemens' commitment to this space has been questioned as management continues a seemingly endless review of the businesses in which it wants to compete for the long term.

Molecular diagnostics is a different story, though. Roche has an exceptionally strong presence in this market, and Abbott has a credible footprint, while Danaher does not. As this is a large market (over $3 billion today) and one of the fastest-growing segments of diagnostics, this could be a focus for future growth, whether internally driven or through M&A.

Several internal growth opportunities
Danaher is a highly acquisitive company, and that is not likely to change. While the prospects for a large deal are tantalizing, I wouldn't sleep on the company's prospects for internally driven growth as well.

Ballast water treatment could be a multibillion dollar opportunity for the company's Environmental segment. Likewise, the product ID space is a multibillion dollar market where Danaher already appears to have about 20% share, even as it competes with Dover in the printing sub-market. Given the opportunities to strengthen its hand in hardware and software, I would not be surprised if this were an area of focus for M&A, but there is ample room for internal growth as well.

The bottom line
I expect Danaher to post mid-single digit revenue and FCF growth over the long term, with M&A likely to continue to factor as a major part of the company's strategy. That leads to a DCF-based fair value of around $71 today. Although that is below the current stock price, I calculate my discount rates on a required return basis, so the worst I can say about Danaher is that it is not so likely to beat the market year in and year out at today's price. Were the stock to pull back into the $60's, I would seriously consider adding shares with the intention of holding for many years.

Danaher may have serious trouble catching up with this stock in 2014...
There’s a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Stephen D. Simpson, CFA owns shares of Roche. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers